Advertisement
Skip to Content

Halozyme Therapeutics Inc HALO Stock Quote

| Rating as of

NASDAQ: HALO

Last close prices updated as of Feb 01, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 52.17
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Mid Growth
  • Day Range 51.32  –  52.62
  • Year Range 32.00  –  59.46
  • Market Cap 7.0541 Bil
  • Volume / Avg 886,010.0 /  1.3 Mil
  • Price / Sales 12.65
  • Price / Book 72.17
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis HALO

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics HALO

Company Profile HALO

Business Description

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Contact
11388 Sorrento Valley Road
San Diego, CA, 92121
Industry Biotechnology
Employees 145

FAQs for Halozyme Therapeutics Inc Stock

No. HALO does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

HALO’s market cap is 7.05 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

HALO’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

HALO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare HALO’s historical performance against its industry peers and the overall market.